The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with hydrochlorothiazide on pulse wave velocity and central blood pressure
Abstrakt
Background and aim: The aim of the study was to establish the effect of valsartan and combination of valsartan and hydrochlorothiazide (HCTZ) on pulse wave velocity (PWV) and central blood pressure (CBP) in a large population of patients with mild to moderate arterial hypertension. Methods: This was an international, multicentre, open-label, prospective trial.
After one week of washout in previously treated patients, 74 subjects were treated with valsartan or valsartan combined with HCTZ for 16 weeks according to the protocol. Naive patients received the treatment immediately.
During the active treatment, four visits were planned for each patient to obtain data for the primary and secondary efficacy. At the beginning and at the end of the study PWV and CBP were determined with central arterial pressure waveform analysis (SphygmoCor (R), Atcor Medical).
This study is registered with clinicaltrialsregister.eu, EudraCT number 2012-005129-57. Results: The results of the present VICTORY trial showed that valsartan and combination of valsartan and HCTZ effectively reduced the brachial blood pressure in patients with mild to moderate arterial hypertension as well as PWV, central systolic blood pressure and central diastolic blood pressure.
The effects on the augmentation index were not statistically significant. Conclusions: Valsartan and valsartan/HCTZ improve arterial stiffness in patients with mild to moderate hypertension.